Lisinopril for kidney disease
Pro Research Analysisby 
Searched over 200M research papers
Lisinopril for Kidney Disease: A Comprehensive Review
Introduction to Lisinopril and Kidney Disease
Lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, is widely used to manage hypertension and heart failure. Its role in treating kidney disease, particularly diabetic nephropathy and other forms of chronic kidney disease (CKD), has been extensively studied. This article synthesizes findings from multiple research studies to provide a clear understanding of the efficacy and safety of lisinopril in kidney disease management.
Lisinopril in Diabetic Nephropathy
Efficacy in Reducing Albuminuria
Several studies have demonstrated that lisinopril effectively reduces albuminuria, a key marker of kidney damage, in patients with diabetic nephropathy. In a study comparing lisinopril to atenolol, lisinopril significantly reduced urinary albumin excretion by 55%, compared to 15% with atenolol, indicating a superior effect in reducing albuminuria . Another study confirmed that lisinopril reduced albuminuria more effectively than atenolol, with a 45% reduction in the lisinopril group versus 12% in the atenolol group .
Impact on Glomerular Filtration Rate (GFR)
The effect of lisinopril on the decline of GFR, a measure of kidney function, has been mixed. In the same comparative study with atenolol, both drugs showed similar rates of GFR decline over time, suggesting that while lisinopril is effective in reducing albuminuria, it may not significantly slow the decline in GFR compared to other antihypertensive treatments 18.
Combination Therapy with Lisinopril
ACE Inhibitors and ARBs
Combining ACE inhibitors like lisinopril with angiotensin-receptor blockers (ARBs) has been explored to enhance kidney protection. However, a study on combination therapy with lisinopril and losartan in diabetic nephropathy patients was halted early due to safety concerns, including increased risks of hyperkalemia and acute kidney injury, without significant benefits in slowing disease progression .
Lisinopril and GLP-1R Agonists
In a mouse model of diabetic kidney disease, combining lisinopril with the GLP-1R agonist semaglutide showed promising results. The combination improved blood pressure, reduced albuminuria, and ameliorated kidney histopathology more effectively than either treatment alone, suggesting potential benefits of such combination therapies in clinical settings .
Lisinopril in Non-Diabetic Kidney Disease
Mild Proteinuric Non-Diabetic Nephropathies
Lisinopril has also been studied in non-diabetic CKD patients with mild proteinuria. A study found that lisinopril significantly slowed the decline in renal function compared to other antihypertensive agents, supporting its renoprotective effects beyond blood pressure control .
Normotensive Patients with IDDM
In normotensive patients with insulin-dependent diabetes mellitus (IDDM) and normoalbuminuria or microalbuminuria, lisinopril was shown to slow the progression of renal disease. The greatest benefit was observed in patients with microalbuminuria, highlighting the importance of early intervention with ACE inhibitors in diabetic patients 610.
Safety and Adverse Effects
While lisinopril is generally well-tolerated, its use can be associated with adverse effects such as hyperkalemia and acute kidney injury, particularly when used in combination with other RAAS inhibitors. Monitoring and managing these risks are crucial in clinical practice to ensure patient safety 29.
Conclusion
Lisinopril is a valuable therapeutic option for managing kidney disease, particularly in reducing albuminuria in diabetic nephropathy and slowing disease progression in non-diabetic CKD. While combination therapies may offer additional benefits, they also pose increased risks that must be carefully managed. Early intervention with lisinopril in patients with microalbuminuria can significantly impact the progression of renal disease, underscoring its importance in kidney disease management.
Sources and full results
Most relevant research papers on this topic
MO069: Therapeutic Effects of Semaglutide as Mono and Combination Treatment with Lisinopril in a Mouse Model of Hypertension-Accelerated Diabetic Kidney Disease
Semaglutide, alone or combined with lisinopril, significantly improves blood pressure, albuminuria, and glomerulosclerosis in a mouse model of hypertension-accelerated diabetic kidney disease.
Effect of Lisinopril on the progression of renal insufficiency in mild proteinuric non-diabetic nephropathies.
Lisinopril has a specific renoprotective effect in addition to blood pressure control in patients with mild proteinuria, slowing the progression of non-diabetic chronic renal diseases.
DOI